99359-32-7

Basic information

• Product Name: METHYL 4-BROMO-L-PHENYLALANINATE HYDROCHLORIDE
• Synonyms: METHYL 4-BROMO-L-PHENYLALANINATE HYDROCHLORIDE;Methyl 4-broMo-l-phenylalaninate, HCl;(S)-Methyl 2-aMino-3-(4-broMophenyl)propanoate hydrochloride;H-Phe(4-Br)-Ome.HCl;4-Bromo-L-phenylalanine methyl ester HCl;L-4-Bromophenylalanine methyl ester hydrochloride;4-Bromo-L-phenylalanine methyl ester hydrochloride;H-Phe(4-Br)
• CAS NO: 99359-32-7
• Molecular Formula: C10H13BrClNO2
• Molecular Weight: 294.57
• Mol File: 99359-32-7.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: METHYL 4-BROMO-L-PHENYLALANINATE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-BROMO-L-PHENYLALANINATE HYDROCHLORIDE(99359-32-7)
• EPA Substance Registry System: METHYL 4-BROMO-L-PHENYLALANINATE HYDROCHLORIDE(99359-32-7)

Safety Data

• Hazardous Substances Data: 99359-32-7(Hazardous Substances Data)

Usage

Uses

Methyl 4-bromo-L-phenylalaninate, HCl

Upstream product

• 67-56-1 methanol 
• 24250-84-8 H-p-BrPhe-OH 
• 62129-39-9 4-bromo-N-{[(1,1-dimethylethyl)oxy]carbonyl}-L-phenylalanine 
• 14091-15-7 p-bromo-DL-phenylalanine 
• 62561-74-4 (2R)-2-amino-3-(4-bromophenyl)propanoic acid 

Downstream Products

• 1378243-33-4 C₂₂H₃₂BrN₃O₅S 
• 24250-84-8 H-p-BrPhe-OH 
• 62561-74-4 (2R)-2-amino-3-(4-bromophenyl)propanoic acid 
• 1616735-89-7 C₂₀H₂₅N₅O₄ 
• 1616735-97-7 C₁₄H₁₅N₅O₂*C₂HF₃O₂ 
• 132067-41-5 methyl (±)-3-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate 
• 1431556-44-3 C₁₃H₁₆BrNO₄ 
• 1431556-69-2 C₁₃H₁₆BrNO₄ 

Relevant articles and documents

Development of sulfahydantoin derivatives as β-lactamase inhibitors

Sulfahydantoin-based molecules may provide a means to counteract antibiotic resistance, which is on the rise. These molecules may act as inhibitors of β-lactamase enzymes, which are key in some resistance mechanisms. In this paper, we report on the synthe

Method for synthesizing AHU377 calcium salt

The invention discloses a method for synthesizing an AHU377 calcium salt. The method comprises the following steps: reacting 4-bromo-D-phenylalanine with thionyl chloride, reacting obtained methyl 4-bromo-D-phenylalaninate hydrochloride with BOC acid anhydride, reacting the obtained reaction product with phenylmagnesium bromide to obtain N-tert-butyloxycarbonyl-amino-4,4-biphenyl-R-alanine methylester, reacting the N-tert-butyloxycarbonyl-amino-4,4-biphenyl-R-alanine methyl ester with sodium borohydride, reacting the obtained reaction product with ethyl 2-(triphenylphosphoranylidene)propionate to obtain ethyl (4R)-5-[1,1'-biphenyl]-4-yl-4-[[tert-butoxycarbonyl]amino]-2-methyl-2-pentenoate, reacting the ethyl (4R)-5-[1,1'-biphenyl]-4-yl-4-[[tert-butoxycarbonyl]amino]-2-methyl-2-pentenoatewith lithium hydroxide, performing catalytic hydrogenation, reacting the obtained catalytic hydrogenation product with thionyl chloride to obtain ethyl (2R, 4S)-5- ([1,1-biphenyl)-4-amino-2-methylpentenoate hydrochloride, and stirring and reacting the ethyl (2R, 4S)-5- ([1,1-biphenyl)-4-amino-2-methylpentenoate hydrochloride, calcium chloride and succinic anhydride to obtain the target product.The method has the advantages of simple steps, mild reaction conditions, high purity and high yield.

HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE

Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (RS)-3-Cyclopropyl-2-{4-[3-methyl-4((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (R)-1-(4′-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.